Skip to search formSkip to main contentSkip to account menu

decernotinib

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Selective Inhibition of Janus Kinase 3 Has No Impact on Infarct Size or Neurobehavioral Outcomes in Permanent Ischemic Stroke in Mice
Janus kinase 3 (JAK3) is associated with the common gamma chain of several interleukin (IL) receptors essential to inflammatory… 
2016
2016
Editorial: A Novel Genetic Association With Systemic Sclerosis: The Utility of Whole‐Exome Sequencing in Autoimmune Disease
In the August 2013 issue of Arthritis & Rheumatism, an editorial by Okada and Plenge proclaimed the dawn of “the age of whole… 
2015
2015
SAT0227 The Effect of Deuteration of VX-509 (Decernotinib) on Drug-Drug Interactions (DDI) with Midazolam
Background VX-509 is an oral selective Janus Kinase 3 inhibitor that has been studied in patients with rheumatoid arthritis (RA… 
2014
2014
OP0151 A Phase 2B, 24-Week Study of VX-509 (DECERNOTINIB), an Oral Selective Janus Kinase 3 Inhibitor, in Combination with Background Methotrexate in Rheumatoid Arthritis
Background VX-509 is an oral selective JAK3 inhibitor being evaluated for the treatment of rheumatoid arthritis (RA). This was a… 
2014
2014
THU0242 Vx-509 (DECERNOTINIB) Treatment Reduces Levels of Markers for Immune Activation, Bone Degradation and Inflammation but not Interferon Signaling in Patients with Rheumatoid Arthritis
Background Janus kinase 3 (JAK3) plays a critical role in gamma-chain cytokine signal transduction and is essential for… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)